Literature DB >> 22319780

Live and let die: a new suicide gene therapy moves to the clinic.

Richard A Morgan1.   

Abstract

Mesh：

Year:  2012        PMID： 22319780      PMCID： PMC3255581          DOI： 10.1038/mt.2011.273

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  11 in total

1.  A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency.

Authors:  Salima Hacein-Bey-Abina; Christof von Kalle; Manfred Schmidt; Françoise Le Deist; Nicolas Wulffraat; Elisabeth McIntyre; Isabelle Radford; Jean-Luc Villeval; Christopher C Fraser; Marina Cavazzana-Calvo; Alain Fischer
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

2.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

Authors:  Richard A Morgan; James C Yang; Mio Kitano; Mark E Dudley; Carolyn M Laurencot; Steven A Rosenberg
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

3.  Gene therapy fulfilling its promise.

Authors:  Donald B Kohn; Fabio Candotti
Journal:  N Engl J Med       Date:  2009-01-29       Impact factor: 91.245

4.  Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial.

Authors:  Renier Brentjens; Raymond Yeh; Yvette Bernal; Isabelle Riviere; Michel Sadelain
Journal:  Mol Ther       Date:  2010-04       Impact factor: 11.454

5.  Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy.

Authors:  F L Moolten
Journal:  Cancer Res       Date:  1986-10       Impact factor: 12.701

Review 6.  Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation.

Authors:  Maria Teresa Lupo-Stanghellini; Elena Provasi; Attilio Bondanza; Fabio Ciceri; Claudio Bordignon; Chiara Bonini
Journal:  Hum Gene Ther       Date:  2010-03       Impact factor: 5.695

7.  Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation.

Authors:  Siok-Keen Tey; Gianpietro Dotti; Cliona M Rooney; Helen E Heslop; Malcolm K Brenner
Journal:  Biol Blood Marrow Transplant       Date:  2007-05-29       Impact factor: 5.742

8.  Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation.

Authors:  William R Burns; Zhili Zheng; Steven A Rosenberg; Richard A Morgan
Journal:  Blood       Date:  2009-07-09       Impact factor: 22.113

9.  Inducible apoptosis as a safety switch for adoptive cell therapy.

Authors:  Antonio Di Stasi; Siok-Keen Tey; Gianpietro Dotti; Yuriko Fujita; Alana Kennedy-Nasser; Caridad Martinez; Karin Straathof; Enli Liu; April G Durett; Bambi Grilley; Hao Liu; Conrad R Cruz; Barbara Savoldo; Adrian P Gee; John Schindler; Robert A Krance; Helen E Heslop; David M Spencer; Cliona M Rooney; Malcolm K Brenner
Journal:  N Engl J Med       Date:  2011-11-03       Impact factor: 91.245

10.  HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia.

Authors:  C Bonini; G Ferrari; S Verzeletti; P Servida; E Zappone; L Ruggieri; M Ponzoni; S Rossini; F Mavilio; C Traversari; C Bordignon
Journal:  Science       Date:  1997-06-13       Impact factor: 47.728
View more
  10 in total

Review 1.  Current advances in T-cell-based cancer immunotherapy.

Authors:  Mingjun Wang; Bingnan Yin; Helen Y Wang; Rong-Fu Wang
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

Review 2.  Emerging Therapies for Hepatocellular Carcinoma (HCC).

Authors:  Eesha Chakraborty; Devanand Sarkar
Journal:  Cancers (Basel)       Date:  2022-06-04       Impact factor: 6.575

3.  Suicide Gene Therapy for Cancer - Current Strategies.

Authors:  Paul Zarogoulidis; Kaid Darwiche; Antonios Sakkas; Lonny Yarmus; Haidong Huang; Qiang Li; Lutz Freitag; Konstantinos Zarogoulidis; Marek Malecki
Journal:  J Genet Syndr Gene Ther       Date:  2013-08-09

4.  Novel approaches to enhance the specificity and safety of engineered T cells.

Authors:  Victor D Fedorov; Michel Sadelain; Christopher C Kloss
Journal:  Cancer J       Date:  2014 Mar-Apr       Impact factor: 3.360

5.  Enzyme Prodrug Therapy Engineered into Electrospun Fibers with Embedded Liposomes for Controlled, Localized Synthesis of Therapeutics.

Authors:  Rona Chandrawati; Morten T J Olesen; Thatiane C C Marini; Gurpal Bisra; Anne Géraldine Guex; Marcelo G de Oliveira; Alexander N Zelikin; Molly M Stevens
Journal:  Adv Healthc Mater       Date:  2017-07-12       Impact factor: 9.933

6.  Ovarian cancer gene therapy using HPV-16 pseudovirion carrying the HSV-tk gene.

Authors:  Chien-Fu Hung; An Jen Chiang; Hsiao-Hsuan Tsai; Martin G Pomper; Tae Heung Kang; Richard R Roden; T-C Wu
Journal:  PLoS One       Date:  2012-07-17       Impact factor: 3.240

7.  How (specific) would like your T-cells today? Generating T-cell therapeutic function through TCR-gene transfer.

Authors:  Inbal Daniel-Meshulam; Shlomo Ya'akobi; Chen Ankri; Cyrille J Cohen
Journal:  Front Immunol       Date:  2012-07-06       Impact factor: 7.561

8.  Targeting Multiple Tumors Using T-Cells Engineered to Express a Natural Cytotoxicity Receptor 2-Based Chimeric Receptor.

Authors:  Vasyl Eisenberg; Katerina Shamalov; Shimrit Meir; Shiran Hoogi; Rhitajit Sarkar; Shirel Pinker; Gal Markel; Angel Porgador; Cyrille J Cohen
Journal:  Front Immunol       Date:  2017-09-29       Impact factor: 7.561

9.  Development of selective cytotoxic viral vectors for concentration of undifferentiated cells in cardiomyocytes derived from human induced pluripotent stem cells.

Authors:  Ken Kono; Rumi Sawada; Takuya Kuroda; Satoshi Yasuda; Satoko Matsuyama; Akifumi Matsuyama; Hiroyuki Mizuguchi; Yoji Sato
Journal:  Sci Rep       Date:  2019-03-06       Impact factor: 4.379

10.  Engineering Extracellular Vesicles with the Tools of Enzyme Prodrug Therapy.

Authors:  Gregor Fuhrmann; Rona Chandrawati; Paresh A Parmar; Timothy J Keane; Stephanie A Maynard; Sergio Bertazzo; Molly M Stevens
Journal:  Adv Mater       Date:  2018-02-23       Impact factor: 30.849
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.